nyse:bmy
|
3625658
|
Mar 23rd, 2024 12:00AM
|
Juno Therapeutics, Inc.
|
27K
|
142.00
|
Open
|
|
Mar 23rd, 2024 01:46AM
|
Mar 23rd, 2024 07:47PM
|
We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver innovative medicines for patients fighting serious diseases. Visit www.bms.com to learn more about our work to produce the next generation of medicines to treat cancer and other serious diseases.
For more information on the acquisition, see our press release at: http://bit.ly/3UbQcnl
|
Open
|
Biotechnology, Immunotherapy, and cell therapy
|
Open
|
400 Dexter Ave N.
|
Seattle
|
WA
|
US
|
98109
|
|
Bristol-Myers Squibb
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:bmy
|
3810454
|
Mar 23rd, 2024 12:00AM
|
MyoKardia
|
14K
|
34.00
|
Open
|
|
Mar 23rd, 2024 01:46AM
|
Mar 23rd, 2024 07:47PM
|
We officially combined with Bristol Myers Squibb to further strengthen our scientific capabilities and treatments for cardiovascular patients. Visit www.bms.com to learn more about our work to produce the next generation of medicines for patients with serious cardiovascular disease.
For more information on the acquisition, see our press release at: https://one.bms.com/40FsT7W
|
Open
|
Genetic Heart Disease, Cardiomyopathy, biotechnology, cardiovascular disease, heart failure, precision medicine, therapeutics, drug discovery, drug development, and R&D
|
Open
|
1000 Sierra Point Parkway
|
Brisbane
|
California
|
US
|
94005
|
|
Bristol-Myers Squibb
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:bmy
|
8348
|
Mar 23rd, 2024 12:00AM
|
Celgene
|
275K
|
2588
|
Open
|
|
Mar 23rd, 2024 01:46AM
|
Mar 23rd, 2024 07:47PM
|
We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver innovative medicines for patients fighting serious diseases. Visit www.bms.com to continue to learn more about our work to produce the next generation of medicines to treat cancer and other serious diseases.
For more information on the acquisition, see our press release at: http://bit.ly/3UbQcnl
|
Open
|
Hematology, Oncology, Inflammation, Immunology, Cancer, R&D, Innovation, Immunooncology, biopharma, Epigenetics, Protein Homeostasis, Translation Medicine, and Orphan diseases
|
Open
|
86 Morris Avenue
|
Summit
|
New Jersey
|
US
|
07901
|
|
Bristol-Myers Squibb
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:bmy
|
1773
|
Mar 23rd, 2024 12:00AM
|
Bristol Myers Squibb
|
1.4M
|
37255
|
Open
|
|
Mar 23rd, 2024 01:46AM
|
Mar 23rd, 2024 07:47PM
|
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome.
Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients.
Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do.
Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
|
Open
|
biotechnology, innovation, great place to work, pharmaceuticals, research and development, and healthcare
|
Open
|
3401 Princeton Pike
|
Lawrence Township
|
NJ
|
US
|
08648
|
|
Bristol-Myers Squibb
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:bmy
|
1773
|
Mar 22nd, 2024 12:00AM
|
Bristol Myers Squibb
|
1.4M
|
37257
|
Open
|
|
Mar 22nd, 2024 01:47AM
|
Mar 22nd, 2024 07:35PM
|
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome.
Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients.
Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do.
Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
|
Open
|
biotechnology, innovation, great place to work, pharmaceuticals, research and development, and healthcare
|
Open
|
3401 Princeton Pike
|
Lawrence Township
|
NJ
|
US
|
08648
|
|
Bristol-Myers Squibb
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:bmy
|
3810454
|
Mar 22nd, 2024 12:00AM
|
MyoKardia
|
14K
|
34.00
|
Open
|
|
Mar 22nd, 2024 01:47AM
|
Mar 22nd, 2024 07:35PM
|
We officially combined with Bristol Myers Squibb to further strengthen our scientific capabilities and treatments for cardiovascular patients. Visit www.bms.com to learn more about our work to produce the next generation of medicines for patients with serious cardiovascular disease.
For more information on the acquisition, see our press release at: https://one.bms.com/40FsT7W
|
Open
|
Genetic Heart Disease, Cardiomyopathy, biotechnology, cardiovascular disease, heart failure, precision medicine, therapeutics, drug discovery, drug development, and R&D
|
Open
|
1000 Sierra Point Parkway
|
Brisbane
|
California
|
US
|
94005
|
|
Bristol-Myers Squibb
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:bmy
|
8348
|
Mar 22nd, 2024 12:00AM
|
Celgene
|
275K
|
2588
|
Open
|
|
Mar 22nd, 2024 01:47AM
|
Mar 22nd, 2024 07:35PM
|
We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver innovative medicines for patients fighting serious diseases. Visit www.bms.com to continue to learn more about our work to produce the next generation of medicines to treat cancer and other serious diseases.
For more information on the acquisition, see our press release at: http://bit.ly/3UbQcnl
|
Open
|
Hematology, Oncology, Inflammation, Immunology, Cancer, R&D, Innovation, Immunooncology, biopharma, Epigenetics, Protein Homeostasis, Translation Medicine, and Orphan diseases
|
Open
|
86 Morris Avenue
|
Summit
|
New Jersey
|
US
|
07901
|
|
Bristol-Myers Squibb
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:bmy
|
3625658
|
Mar 22nd, 2024 12:00AM
|
Juno Therapeutics, Inc.
|
27K
|
142.00
|
Open
|
|
Mar 22nd, 2024 01:47AM
|
Mar 22nd, 2024 07:35PM
|
We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver innovative medicines for patients fighting serious diseases. Visit www.bms.com to learn more about our work to produce the next generation of medicines to treat cancer and other serious diseases.
For more information on the acquisition, see our press release at: http://bit.ly/3UbQcnl
|
Open
|
Biotechnology, Immunotherapy, and cell therapy
|
Open
|
400 Dexter Ave N.
|
Seattle
|
WA
|
US
|
98109
|
|
Bristol-Myers Squibb
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:bmy
|
3810454
|
Mar 21st, 2024 12:00AM
|
MyoKardia
|
14K
|
33.00
|
Open
|
|
Mar 21st, 2024 06:19PM
|
Mar 21st, 2024 06:19PM
|
We officially combined with Bristol Myers Squibb to further strengthen our scientific capabilities and treatments for cardiovascular patients. Visit www.bms.com to learn more about our work to produce the next generation of medicines for patients with serious cardiovascular disease.
For more information on the acquisition, see our press release at: https://one.bms.com/40FsT7W
|
Open
|
Genetic Heart Disease, Cardiomyopathy, biotechnology, cardiovascular disease, heart failure, precision medicine, therapeutics, drug discovery, drug development, and R&D
|
Open
|
1000 Sierra Point Parkway
|
Brisbane
|
California
|
US
|
94005
|
|
Bristol-Myers Squibb
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:bmy
|
1773
|
Mar 21st, 2024 12:00AM
|
Bristol Myers Squibb
|
1.4M
|
37266
|
Open
|
|
Mar 21st, 2024 06:19PM
|
Mar 21st, 2024 06:19PM
|
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome.
Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients.
Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do.
Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
|
Open
|
biotechnology, innovation, great place to work, pharmaceuticals, research and development, and healthcare
|
Open
|
3401 Princeton Pike
|
Lawrence Township
|
NJ
|
US
|
08648
|
|
Bristol-Myers Squibb
|
Health Care
|
Pharmaceuticals & Biotechnology
|